The Huntington Study Group issued a press release about a new study to treat the movements associated with HD, known as chorea. The study, called KINECT-HD, will take place at 55 sites across the US and Canada. Some locations have begun enrolling participants, aged 18 to 75, with a clinical diagnosis of HD. The trial lasts 18 weeks and will include a screening period, a treatment period, and a follow-up period. Information on currently recruiting sites will continue to be updated at www.hdtrialfinder.org and at https://clinicaltrials.gov/ct2/show/NCT04102579.
HDBuzz Covers New Huntingtin-lowering Strategy
Last week we shared news of a newly published huntingtin-lowering strategy that helps cells to take out the trash. This week, HDSA Berman-Topper fellow Tamara Maiuri covers the work on HDBuzz in greater detail!
HD Insights Podcast
“The goal of the HD Insights podcast is to provide further in-depth insights about the people working on treatments that make a difference for those impacted by HD, and to share the interesting stories about their journey,” writes the Huntington Study Group (HSG). This week’s episode, recorded at the annual HSG conference in Sacramento, is a conversation with Dr. Martha Nance, who directs the HDSA Center of Excellence at Hennepin County Medical Center in Minneapolis, MN. She speaks about the value of a multidisciplinary approach to HD, caring for folks with late-stage HD symptoms, genetic testing, and the impact of HD on youth.
uniQure Prioritizes Huntington’s disease
Three weeks ago we announced that the first gene therapy trial for HD has begun screening for enrollment. This week uniQURE released a video in which CEO Matt Kapusta speaks about the company’s priorities in 2020. Their huntingtin-lowering gene therapy, AMT-130, is on that list.